BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Oncology: Breast Cancer: Triple-Negative Disease Coverage

Retail Price: $22,000.00

*BioMedTracker Subscriber Price: $15,000.00 - click here to log in

May 09, 2018

Triple-negative breast cancer is characterized by the absence of estrogen and progesterone receptors, and does not involve overexpression of human epidermal growth factor 2 (HER2). It is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. Overall, breast cancer is the second most common cancer and the second leading cause of cancer-related deaths in women worldwide. In the US, breast cancer is the third leading cause of cancer-related deaths, regardless of gender, behind lung cancer and colorectal cancer.

This Datamonitor Healthcare Disease report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.

Disease Group Covered: Oncology
Back to the top Back to the top